One earlier published meta-analysis indicated a benefit from combination therapy compared to ACE-inhibitor alone on readmission rates for heart failure [17], but failed to report overall readmission rates which are of particular interest based on the observed increase in adverse effects observed in the 2 meta-analyses mentioned above. This evidence concerns the gene ACE and heart failure.